The role of IL-10 in inflammatory bowel disease: 'Of mice and men'

Toxicologic Pathology

Volumn 27, Issue 1, 1999, Pages 123-133

  Leach, Michael W ^a   Davidson, Natalie J ^a   Fort, Madeline M ^a   Powrie, Fiona ^b   Rennick, Donna M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Colitis; Interleukin 10; Mucosal immunity; T cell; Thl

Indexed keywords

INTERLEUKIN 10;

ANIMAL MODEL; COLON CROHN DISEASE; CONFERENCE PAPER; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; MACROPHAGE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TOXICITY TESTING; ULCERATIVE COLITIS;

ANIMALIA; RODENTIA;

EID: 0032978528     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339902700124     Document Type: Conference Paper

References (137)

1. Abbas AK, Murphy KM, and Sher A (1996). Functional diversity of helper T lymphocytes. Nature 383: 787-793.
2. high T cells to SCID recipients. J. Immunol. 158: 3464-3473.
3. Autenrieth IB, Bucheler N, Bohn E, Heinze G, and Horak I (1997). Cytokine mRNA expression in intestinal tissue of interleukin-2 deficient mice with bowel inflammation. Gut 41: 793-800.
4. Beagley KW, Fujihashi K, Lagoo AS, Lagoo-Deenadaylan S, Black CA, Murray AM, Sharmanov AT, Yamamoto M, McGhee JR, Elson CO, and Kiyono H (1995). Differences in intraepithelial lymphocyte T cell subsets isolated from murine small versus large intestine. J. Immunol. 154: 5611-5619.
5. + TH1-like responses. J. Clin. Invest. 98: 1010-1020.
6. + TCR αβ T cells of athymic origin in histocompatible severe combined immunodeficient (SCID) mice. Clin. Exp. Immunol. 112: 443-452.
7. Brandwein SL, McCabe RP, Cong Y, Waites KB, Ridwan BU, Dean PA, Ohkusa T, Birkenmeier EH, Sundberg JP, and Elson CO (1997). Spontaneously colitis C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora. J. Immunol. 159: 44-52.
8. Breese E, Braegger CP, Corrigan CJ, Walker-Smith JA, and MacDonald TT (1993). Interleukin-2- and interferon-γ-secreting T cells in normal and diseased human intestinal mucosa. Immunology 78: 127-131.
9. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, Walker-Smith JA, and MacDonald TT (1994). Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106: 1455-1466.
10. Bregenholt S and Claesson MH (1998). Increased intracellular Th1 cytokines in SCID mice with inflammatory bowel disease. Eur. J. Immunol. 28: 379-389.
11. Bregenholt S, Delbro D, and Claesson MH (1997). T-cell transfer and cytokine/TCR gene deletion models in the study of inflammatory bowel disease. APMIS 105: 655-662.
12. Cahill RJ, Foltz CJ, Fox JG, Dangler CA, Powrie F, and Schauer DB (1997). Inflammatory bowel disease: An immunity-mediated condition triggered by bacterial infection with Helicobacter hepaticus. Infect. Immun. 65: 3126-3131.
13. Calkins BM and Mendeloff AI (1995). The epidemiology of idiopathic inflammatory bowel disease. In: Inflammatory Bowel Disease, JB Kirsner and RG Shorter (eds). Williams & Wilkins, Baltimore, Maryland, pp. 31-67.
14. Camerini V, Panwala C, and Kronenberg M (1993). Regional specialization of the mucosal immune system. J. Immunol. 151: 1765-1776.
15. Cao X, Shores EW, Hu-Li J, Anver MR, Kelsall BL, Russell SM, Drago J, Noguchi M, Grinberg A, Bloom ET, Paul WE, Katz SI, Love PE, and Leonard WJ (1995). Defective lymphoid development in mice lacking expression of the common cytokine receptor γ chain. Immunity 2: 223-238.
16. Casini-Raggi V, Kam L, Chong YJT, Fiocchi C, Pizarro TT, and Cominelli F (1995). Mucosal imbalance in IL-I and IL-I receptor antagonist in inflammatory bowel disease. J. Immunol. 154: 2434-2440.
17. Chernoff AE, Granowitz EV, Shapiro L, Vanneir E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Wolff SM, and Dinarello CA (1995). A randomized, controlled trial of IL-10 in humans. J. Immunol. 154: 5492-5499.
18. + T lymphocytes injected into severe combined immunodeficient (SCID) mice lead to an inflammatory and lethal bowel disease. Clin. Exp. Immunol. 104: 491-500.
19. + T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: Increased T helper cell type 1 response and ability to transfer disease. J. Exp. Med. 187: 855-864.
20. Davidson NJ, Fort MM, Müller W, Leach MW, and Rennick DM (1998). Chronic colitis in IL-10′ mice: Insufficient counter regulation of a Th1 response. Int. Rev. Immunol. (in press).
21. Davidson NJ, Hudak SA, Lesley RE, Menon S, Leach MW, and Rennick DM (1998). IL-12, but not interferon-γ, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J. Immunol. 161: 3143-3149.
22. + T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J. Exp. Med. 184: 241-251.
23. de Vries JE (1995). Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann. Med. 27: 537-541.
24. Dianda L, Hanby AM, Wright NA, Sebsteny A, Hayday AC, and Owen MJ (1997). T cell receptor-αβ-deficient mice fail to develop colitis in the absence of a microbial environment. Am. J. Pathol. 150: 91-97.
25. Dionne S, D'Agata D, Hiscott J, Vanounou T, and Seidman EG (1998). Colonic explant production of IL-1 and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD). Clin. Exp. Immunol. 112: 435-442.
26. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, and Meyer zum Büschenfelde KH (1995). Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin. Exp. Immunol. 102: 448-455.
27. Duchmann R, Schmitt E, Knolle P, Meyer zum Büschenfelde KH, and Neurath M (1998). Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur. J. Immunol. 26: 934-938.
28. Ehrhardt RO, Lúdvíksson BR, Gray B, Neurath M, and Strober W (1997). Induction and prevention of colonic inflammation in IL-2-deficient mice. J. Immunol. 158: 566-573.
29. Elson CO (1996). The basis of current and future therapy for inflammatory bowel disease. Am. J. Med. 100: 656-662.
30. Elson CO, Sartor RB, Tennyson GS, and Riddell RH (1995). Experimental models of inflammatory bowel disease. Gastroenterology 109: 1344-1367.
31. + T cells in a transfer model of colitis. J. Immunol 161: 3256-3261.
32. Fox JG (1997). The expanding genus of Helicobacter: Pathogenic and zoonotic potential. Semin. Gastrointest. Dis. 8: 124-141.
33. Fox JG, Van L, Shames B, Campbell J, Murphy JC, and Li X (1996). Persistent hepatitis and enterocolitis in germfree mice infected with Helicobacter hepaticus. Infect. Immun. 64: 3673-3681.
34. Funakoshi K, Sugimura K, Sasakawa T, Bannai H, Anezaki K, Ishizuka K, Yoshida K, Narisawa R, and Asakura H (1995). Study of cytokines in ulcerative colitis. J. Gastroenterol. 30: 61-63.
35. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. J. Immunol. 157: 1261-1270.
36. Gaskins HR, Vondrak-Juergens GL, McCracken BA, and Woolsey JH (1997). Specific-pathogen-free conditions enhance inflammatory bowel disease in T-cell receptor knockout, but not C3H/ HeJBir mice. Lab. Anim. Sci. 47: 650-655.
37. Geissler K (1996). Current status of clinical development of interleukin-10. Curr. Opin. Hematol. 3: 203-208.
38. Gross V, Andus T, Caesar I, Roth M, and Schölmerich J (1992). Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 102: 514-519.
39. + T cells. J. Exp. Med. 184: 19-29.
40. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389: 737-742.
41. Hagenbaugh A, Sharma S, Dubinett SM, Wei SHY, Aranda R, Cheroutre H, Fowell DJ, Binder S, Tsao B, Locksley RM, Moore KW, and Kronenberg M (1997). Altered immune responses in interleukin 10 transgenic mice. J. Exp. Med. 185: 2101-2110.
42. Haines DC, Gorelick PL, Battles JK, Pike KM, Anderson RJ, Fox JG, Taylor NS, Shen Z, Dewhirst FE, Anver MR, and Ward JM (1998). Inflammatory large bowel disease in immunodeficient rats naturally and experimentally infected with Helicobacter bilis. Vet. Pathol. 35: 202-208.
43. 2m: An animal model of HLA-B27-associated human disorders. Cell 63: 1099-1112.
44. Hara J, Ohtani H, Matsumoto T, Nakamura S, Kitano A, Arakawa T, Nagura H, and Kobayashi K (1997). Expression of costimulatory molecules B7-1 and B7-2 in macrophages and granulomas of Crohn's disease: Demonstration of cell-to-cell contact with T lymphocytes. Lab. Invest. 77: 175-184.
45. Harper PH, Lee ECG, Kettlewell MGW, Bennett MK, and Jewell DP (1985). Role of the faecal stream in the maintenance of Crohn's colitis. Gut 26: 279-284.
46. Herfarth HH, Mohanty SP, Rath HC, Tonkonogy S, and Sartor RB (1996). Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut 39: 836-845.
47. Hermiston ML and Gordon JI (1995). Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 270: 1203-1207.
48. Hollander D (1993). Permeability in Crohn's disease: Altered barrier functions in healthy relatives? Gastroenterology 104: 1848-1851.
49. Holländer GA, Simpson SJ, Mizoguchi E, Nichoglannopoulou A, She J, Gutierrez-Ramos JC, Bhan AK, Burakoff SJ, Wang B. and Terhorst C (1995). Severe colitis in mice with aberrant thymic selection. Immunity 3: 27-38.
50. + T cells and proinflammatory Th1-type cytokines. J. Immunol. 158: 1068-1077.
51. + T cells from INF-γ knockout mice do not induce wasting disease. J. Autoimmun. 10: 455-459.
52. Krämer S, Schimpl A. and Hünig TR (1995). Immunopathology of interleukin (IL) 2-deficient mice: Thymus dependence and sup-pression by thymus-dependent cells with an intact IL-2 gene. J. Exp. Med. 182: 1769-1776.
53. Kucharzik T, Lügering N, Adolf M, Donischke W, and Stoll R (1997). Synergistic effect of immunorcgulatory cytokines on peripheral blood monocytes from patients with inflammatory bowel disease. Dig. Dis. Sci. 42: 805-812.
54. Kucharzik T, Lügering N, Pauels HG, Domschke W, and Stoll R (1998). IL-4. IL-10 and IL-13 down-regulate monocyte-chemoattracting protein-1 (MCP-1) production in activated intestinal epithelial cells. Clin. Exp. Immunol 111: 152-157.
55. Kucharzik T. Lügering N, Weigelt H. Adolf M, Domschke W, and Stoll R (1996). Immunoregulatory properties of IL-13 in patients with inflammatory bowel disease: comparison with IL-4 and IL-10. Clin. Exp. Immunol. 104: 483-490.
56. Kucharzik T, Stoll R. Lügering N, and Domschke W (1995). Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease. Clin. Exp. Immunol. 100: 452-456.
57. Kühn R, Löhler J, Rennick D, Rajewsky K, and Müller W (1993). Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274.
58. Kulkarni AB, Ward JM, Yaswen L. Mackall CL, Bauer SR, Huh CG, Gress RE. and Kurlsson S (1995). Transforming growth factor-β1 null mice. An animal model for inflammatory disorders. Am. J. Pathol. 146: 264-275.
59. Lalani I, Bhol K, and Ahmed AR (1997). Interleukin-10: Biology, role in inflammation and autoinmmunity. Ann. Allergy Asthma Immunol. 79: 469-483.
60. Lapidus A, Bernell O, Hellers G, and Löfberg R (1998). Clinical course of colorectal Crohn's disease: A 35-year follow-up study of 507 patients. Gastroenterology 114: 1151-1160.
61. Lasher BA (1995). Clinical features, laboratory findings, and course of Crohn's disease. In: Inflammatory Bowel Disease. JB Kirsner and RG Shorter (eds). Williams & Wilkins, Baltimore, Maryland, pp. 344-354.
62. + T cells. Am. J. Pathol. 148: 1503-1515.
63. Lewin KJ, Riddell RH, and Weinstein WM (1992). Inflammatory bowel diseases. In: Gastrointestinal Pathology and Its Clinical Implications, KJ Lewin, RH Riddell, and WM Weinstein (eds). Igaku-Shoin, New York, pp. 812-989.
64. Lúdvíksson BR, Ehrhardt RO, and Strober W (1997). TGF-ß production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonie inflammation in IL-2-deficient mice. J. Immunol. 159: 3622-3628.
65. Lúdvíksson BR, Gray B, Strober W, and Ehrhardt RO (1997). Dysregulated intrathymic development in the IL-2-deficient mouse leads to colitis-inducing thymocytes. J. Immunol. 158: 104-111.
66. Lügering N, Kucharzik T, Stein H, Winde G, Lügering A, Hasilik A, Domschke W, and Stoll R (1998). IL-10 synergizes with IL-4 and IL-13 in inhibiting lysosomal enzyme secretion by human monocytes and lamina propria mononuclear cells from patients with inflammatory bowel disease. Dig. Din. Sci. 43: 706-714.
67. MacDermott RP (1996). Alterations of the mucosal immune system in inflammatory bowel disease. J. Gastroenterol. 31: 907-916.
68. MacDonald TT (1995). Breakdown of tolerance to the intestinal bacterial flora in inflammatory bowel disease (IBD). Clin. Exp. Immunol. 102: 445-447.
69. May GR, Sutherland LR, and Meddings JB (1993). Is small intestinal permeability really increased in relatives of patients with Crohn's disease? Gastroenterology 104: 1627-1632.
70. McDonald SAC, Palmen MJHJ, van Rees EP, and MacDonald TT (1997). Characterization of the mucosal cell-mediated immune response in IL-2 knockout mice before and after the onset of colitis. Immunology 91: 73-80.
71. Merger M and Croitoru K (1998). Infections in the immunopathogenesis of chronic inflammatory bowel disease. Semin, Immunol. 10: 69-78.
72. Mitsuyama K, Sasaki E, Toyonaga A, Ikeda H, Tsuruta O, Irie A, Arima N, Oriishi T, Harada K, Fujisaki K, Sata M, and Tanikawa K (1991). Colonic mucosal interleukin-6 in inflammatory bowel disease. Digestion 50: 104-111.
73. Mizoguchi A, Mizoguchi E, Chiba M, and Bhan AK (1996). Role of appendix in the development of inflammatory bowel disease in TCR-α mutant mice. J. Exp. Med. 184: 707-715.
74. Mizoguchi A, Mizoguchi E, Chiba M, Spiekermann GM, Tonegawa S, Nagler-Andeson C, and Bhan AK (1996). Cytokine imbalance and autoantibody production in T cell receptor-α mutant mice with inflammatory bowel disease. J. Exp. Med. 183: 847-856.
75. Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, and Bhan AK (1997). Suppressive role of B cells in chronic colitis of T cell receptor a mutant mice. J. Exp. Med. 186: 1749-1756.
76. Mizoguchi E, Mizoguchi A, and Bhan AK (1997). Role of cytokines in the early stages of chronic colitis in TCRα-mutant mice. Lab. Invest. 76: 385-397.
77. Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH. Bhan AK, and Tonegawa S (1993). Spontaneous development in inflammatory bowel disease in T cell receptor mutant mice. Cell 75: 275-282.
78. Monteleone G. Biancone L, Marasco R, Morrone G, Marasco O. Luzza F, and Pallone F (1997). Inlerleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112: 1169-1178.
79. + T cells. Res. Immunol. 145: 357-362.
80. + T cells. J. Exp. Med. 178: 237-244.
81. Mosmann TR, Cherwinski H, Bond MW, Giedlon MA, and Coffman RL (1986). Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136: 2348-2357.
82. Moss AA, Carbone JV, and Kressel HY (1978). Radiologic and clinical assessment of broad-spectrum antibiotic therapy in Crohn's disease. Am. J. Roentgenol. 131: 787-790.
83. Murata Y, Ishiguro Y, Itoh J, Munakata A, and Yoshida Y (1995). The role of proinflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis. J. Gastroenterol. 30: 56-60.
84. Murch SH, Braegger CP, Walker-Smith JA, and MacDonald TT (1993). Location of tumour necrosis factor a by immunohistochemistry in chronic inflammatory bowel disease. Gut 34: 1705-1709.
85. Narula SK, Cutler D, and Grint P (1998). Immunomodulation of Crohn's disease by interleukin-10. Agents Actions Suppl. 49: 57-65.
86. Neurath MF, Fuss I, Kelsall B, Presky DH, Waegell W, and Strober W (1996). Experimental granulomatous colitis in mice is abrogated by induction of TGF-β-mediated oral tolerance. J. Exp. Med. 183: 2605-2616.
87. Niessner M and Volk BA (1995). Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin. Exp. Immunol. 101: 428-435.
88. Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, Maggi E, Pupilli C, Tonelli F, and Romagnani S (1997). Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am. J. Pathol. 150: 823-832.
89. Powrie F (1995). T cells in inflammatory bowel disease: Protective and pathogenic roles. Immunity 3: 171-174.
90. + T cells. J. Exp. Med. 183: 2669-2674.
91. + T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int. Immunol. 5: 1461-1471.
92. + T cells. Immunity 1: 553-562.
93. + T-cells in the regulation of inflammatory responses in the intestine. Res. Immunol. 148: 576-581.
94. Prantera C, Zannoni F, Spimpolo N, and Bonfa M (1994). Metronidazole plus ciprofloxacin in the treatment of active, refractory Crohn's disease: Results of an open study. J. Clin. Gastroenterol. 19: 79-80.
95. 2 microglobulin transgenic rats. J. Clin. Invest. 98: 945-953.
96. Reif S, Klein I, Lubin F, Farbstein M, Hallak A, and Gilat T (1997). Pre-illness dietary factors in inflammatory bowel disease. Gut 40: 754-760.
97. + T cell population in severe-combined immunodeficient mice expressing a rearranged, transgenic class I-restricted αβ T cell receptor. Eur. J. Immunol. 25: 1643-1653.
98. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, and Raedler A (1993). Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin. Exp. Immunol. 94: 174-181.
99. Retsky JL and Kraft SC (1995). The extraintestinal manifestations of inflammatory bowel disease. In: Inflammatory Bowel Disease, JB Kirsner and RG Shorter (eds). Williams & Wilkins, Baltimore, Maryland, pp. 474-491.
100. Riddell RH (1995). Pathology of idiopathic inflammatory bowel disease. In: Inflammatory Bowel Disease, JB Kirsner and RG Shorter (eds). Williams & Wilkins, Baltimore, Maryland, pp. 517-552.
101. Robinson M (1997). Optimizing therapy for inflammatory bowel disease. Am. J. Gastroenterol. 92: 12S-17S.
102. Rogler G and Andus T (1998). Cytokines in inflammatory bowel disease. World J. Surg. 22: 382-389.
103. 12-deficient mice. Nat. Genet. 10: 143-149.
104. + T cell receptor αβ T cells in the pathogenesis of murine inflammatory bowel disease. Eur. J. Immunol. 24: 2803-2812.
105. + αβ T cells in the colonic lamina propria of SCID mice with colitis. Eur. J. Immunol. 26: 1156-1163.
106. Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, and Scott H (1994). Increased macrophage subset in inflammatory bowel disease: Apparent recruitment from peripheral blood monocytes. Gut 35: 669-674.
107. Rugtveit J, Nilsen EM, Bakka A, Carlsen H, Brandzaeg P, and Scott H (1997). Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology 112: 1493-1505.
108. Rutgeerts P, Goboes K, Peeters M, Hiele M, Penninckx F, Aerts R, Kerremans R, and Vantrappen G (1991). Effect of faecal stream diversion in recurrence of Crohn's disease in the neoterminal ileum. Lancet 338: 771-774.
109. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, and Kerremans R (1995). Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 108: 1817-1821.
110. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, and Horak I (1993). Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253-261.
111. Sartor RB (1990). Role of intestinal microflora in initiation and perpetuation of inflammatory bowel disease. Can. J. Gastroenterol. 4: 271-277.
112. Sartor RB (1995). Microbial factors in the pathogenesis of Crohn's disease, ulcerative colitis, and experimental intestinal inflammation. In: Inflammatory Bowel Disease, JB Kirsner and RG Shorter (eds). Williams & Wilkins, Baltimore, Maryland, pp. 96-124.
113. Schölmerich J (1997). Immunosuppressive treatment for refractory ulcerative colitis - Where do we stand and where are we going? Eur. J. Gastroenterol. Hepatol. 9: 842-849.
114. Schreiber S, Heinig T, Panzer U, Reinking R, Bouchard A, Stahl PD, and Raedler A (1995). Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology 108: 21-33.
115. Schreiber S, Heinig T, Thiele HG, and Raedler A (1995). Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 108: 1434-1444.
116. Schreiber S, Raedler A, Stenson WF, and MacDermott RP (1992). The role of the mucosal immune system in inflammatory bowel disease. Gastroenterol Clin. North Am. 21: 451-502.
117. Shomer NH, Dangler CA, Schrenzel MD, and Fox JG (1997). Helicobacter bilis-induced inflammatory bowel disease in scid mice with defined flora. Infect. Immun. 65: 4858-4864.
118. Shorter RG, Huizenga KA, and Spencer RJ (1972). A working hypothesis for the etiology and pathogenesis of nonspecific inflammatory bowel disease. Dig. Dis. 17: 1024-1032.
119. + T cells in an experimental model of colitis. Eur. J. Immunol. 27: 17-25.
120. + T cells are responsible for murine interleukin-2-deficient colitis. Eur. J. Immunol. 25: 2618-2625.
121. Simpson SJ, Shah S, Comiskey M, de Jong YP, Wang B, Mizoguchi E, Bhan AK, and Terhorst C (1998). T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon γ expression by T cells. J. Exp. Med. 187: 1225-1234.
122. Singleton JW (1995). Clinical features, course, and laboratory findings in ulcerative colitis. In: Inflammatory Bowel Disease, JB Kirsner and RG Shorter (eds). Williams & Wilkins, Baltimore, Maryland, pp. 335-343.
123. Strober W, Kelsall B, Fuss I, Marth T, Ludviksson B, Ehrhardt R, and Neurath M (1997). Reciprocal INF-γ and TGF-β responses regulate the occurrence of mucosal inflammation. Immunol. Today 18: 61-64.
124. Sundberg JP, Elson CO, Bedigian H, and Birkenmeier EH (1994). Spontaneous, heritable colitis in a new substrain of C3H/HeJ mice. Gastroenterology 107: 1726-1735.
125. + T-cell population mediates development of inflammatory bowel disease in T-cell receptor α chain-deficient mice. Gastroenterology 112: 1876-1886.
126. Tanaka M and Riddell RH (1990). The pathological diagnosis and differential diagnosis of Crohn's disease. Hepato-Gastroenterology 37: 18-31.
127. Thomas ML (1989). The leukocyte common antigen family. Annu. Rev. Immunol. 7: 339-369.
128. Tomoyose M, Mitsuyama K, Ishida H, Toyonaga A, and Tanikawa K (1998). Role of interleukin-10 in a murine model of dextran sulfate sodium-induced colitis. Scand. J. Gastroenterol. 33: 435-440.
129. Tremaine WJ (1997). Refractory IBD: Medical management. Neth. J. Med. 50: S12-S14.
130. van Deventer SJ, Elson CO, and Fedorak RN (1997). Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology 113: 383-389.
131. Wagner N, Löhler J, Kunkel EJ, Ley K, Leung E, Krissansen G, Rajewsky K, and Müller W (1996). Critical role for β7 intergrins in formation of the gut-associated lymphoid tissue. Nature 382: 366-370.
132. Ward JM, Anver MR, Haines DC, Melhorn JM, Gorelick PL, Yan L, and Fox JG (1996). Inflammatory large bowel disease in immunodeficient mice naturally infected with Helicobacter hepaticus. Lab. Anim. Sci. 46: 15-20.
133. Watanabe M, Ueno Y, Yajima T, Okamoto S, Hayashi T, Yamazaki M, Iwao Y, Ishii H, Habu S, Uehira M, Nishimoto H, Ishikawa H, Hata JI, and Hibi T (1998). Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa. J. Exp. Med. 187: 389-402.
134. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, and Alt FW (1995). Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3: 521-530.
135. Wyatt J, Vogelsang H, Hübl W, Waldhöer T, and Lochs H (1993). Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 341: 1437-1439.
136. Yang H and Rotter JI (1995). Genetic aspects of idiopathic inflammatory bowel disease. In: Inflammatory Bowel Disease, JB Kirsner and RG Shorter (eds). Williams & Wilkins, Baltimore, Maryland, pp. 301-331.
137. Youngman KR, Simon PL, West GA, Cominelli F, Rachmilewitz D, Klein JS, and Fiocchi C (1993). Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 104: 749-758.